DM1 ADC ELISA refers to an enzyme-linked immunosorbent assay (ELISA) designed to detect and quantify antibody–drug conjugates (ADCs) that are linked to the cytotoxic payload DM1 (a maytansine derivative). DM1 is commonly used in targeted cancer therapies, where it is conjugated to monoclonal antibodies to selectively deliver the cytotoxic drug to tumor cells while minimizing systemic toxicity. The DM1 ADC ELISA measures the concentration of the conjugated antibody–drug complex in biological samples such as plasma or serum, providing critical pharmacokinetic and pharmacodynamic information.
In research, DM1 ADC ELISA is used to evaluate the pharmacokinetics, bioavailability, and stability of DM1-based ADCs during preclinical and clinical development. Researchers use this assay to monitor how the ADC circulates in the bloodstream, its rate of clearance, and its degradation or deconjugation over time. This information is essential for optimizing dosing strategies, understanding drug–antibody stability, and correlating exposure with efficacy or toxicity in animal models and early-phase clinical trials.
This product is manufactured in USA by Eagle Biosciences.
| Size | 1 x 96 Well |
| Sensitivity | 0.0077 μg/mL |
| Dynamic Range | 0.016 – 1.0 μg/mL |
| Incubation Time | 2 hours 30 minutes |
| Sample Type | Biological Fluids |
| Storage | 2-8°C |
| Alternative Names | maytansinoid DM1 antibody-drug conjugate, trastuzumab emtansine (in the case of HER2-targeted ADC), or antibody–maytansinoid conjugate. |
